Last €38.06 EUR
Change Today -0.68 / -1.75%
Volume 0.0
NK8 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:17 PM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NK8) Snapshot

Open
€38.70
Previous Close
€38.74
Day High
€38.95
Day Low
€38.06
52 Week High
12/23/14 - €38.95
52 Week Low
01/3/14 - €22.90
Market Cap
1.8B
Average Volume 10 Days
13.5
EPS TTM
--
Shares Outstanding
47.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NUVASIVE INC (NK8)

nuvasive inc (NK8) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NK8) Details

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product offering includes a minimally disruptive surgical platform, known Maximum Access Surgery (MAS) that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and various specialized implants. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing consist of allograft (donated human tissue); Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during spine and other surgeries. In addition, the company is developing proprietary total disc replacement devices, which include XL-TDR, a mechanical total disc replacement for lateral lumbar spine applications; and the PCM device for cervical spine applications. It sells its products through independent sales agencies, directly-employed sales shareowners, and distributors to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,358 Employees
Last Reported Date: 03/3/14
Founded in 1997

nuvasive inc (NK8) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
Chief Operating Officer
Total Annual Compensation: $550.0K
President of Global Products & Services
Total Annual Compensation: $520.0K
Executive Vice President of U.S. Sales
Total Annual Compensation: $375.0K
Special Advisor
Total Annual Compensation: $482.5K
Compensation as of Fiscal Year 2013.

nuvasive inc (NK8) Key Developments

NuVasive, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 10:00 AM

NuVasive, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 10:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States.

NuVasive, Inc. Provides Earnings Guidance for the Full Year of 2014

NuVasive, Inc. provides earnings guidance for the full year of 2014. For the period. the company expects 16.5% operating margin for this year. So this year, there's no doubt the tax rate is an all-time high for company. Company has got a tax rate of approximately 70% despite having pretax losses, so company has an expense despite a loss.

NuVasive, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Year 2014

NuVasive, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenue of $189,918,000 against $169,156,000 a year ago. Income before income taxes was $7,101,000 against $8,140,000 a year ago. Consolidated net loss was $1,987,000 against consolidated net income of $7,280,000 a year ago. Net loss attributable to the company was $1,830,000 against net income attributable to the company of $7,511,000 a year ago. Basic and diluted net loss per share was $0.04 against diluted earnings per share of $0.16 a year ago. On a non-GAAP basis, the company reported net income of $9.6 million, or $0.19 per share. The non-GAAP earnings per share calculations exclude the amounts pre-tax: non-cash stock-based compensation of $8.2 million; certain intellectual property litigation expenses of $1.2 million; amortization of intangible assets of $3.1 million; a leasehold related charge of $2.2 million; one-time and acquisition related items of $0.6 million; and non-cash interest expense on convertible notes of $3.7 million. Non-GAAP earnings were $9,592,000 or $0.19 earnings per share. Generated record quarterly free cash flow at $35 million. For the nine months, the company reported revenue of $558,090,000 against $494,358,000 a year ago. Loss before income taxes was $28,854,000 against profit before income taxes of $1,168,000 a year ago. Consolidated net loss was $24,789,000 against consolidated net income of $1,148,000 a year ago. Net loss attributable to the company was $24,194,000 against net income attributable to the company of $1,893,000 a year ago. Basic and diluted net loss per share was $0.52 against diluted earnings per share of $0.4 a year ago. Net cash provided by operating activities was $96,484,000 against $70,133,000 a year ago. Purchases of property and equipment were $45,692,000 against $38,018,000 a year ago. Non-GAAP earnings were $37,512,000 or $0.76 earnings per share. For the year 2014, the company expects revenue of approximately $755.0 million, which includes an incremental headwind from currency in the fourth quarter 2014, or 10% growth over 2013 revenue of $685.2 million; increased from previous guidance of approximately $745.0 million. GAAP loss per share of approximately $0.36 compared to previous guidance of approximately $0.38. Non-GAAP earnings per share of approximately $1.12 increased from previous guidance of approximately $1.11. Non-GAAP operating margin of approximately 16.5% unchanged from previous guidance. GAAP effective tax expense of approximately $7.0 million compared to previous guidance of approximately $6.0 million as a result of increased pre-tax earnings.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €38.06 EUR -0.68

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $45.16 USD -0.17
Cyberonics Inc $55.06 USD +0.43
Globus Medical Inc $24.30 USD -0.07
Integra LifeSciences Holdings Corp $53.90 USD +0.22
Thoratec Corp $32.91 USD +0.10
View Industry Companies
 

Industry Analysis

NK8

Industry Average

Valuation NK8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit www.nuvasive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.